Cargando…
Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications
Heat shock proteins (Hsps) have garnered special attention in cancer therapy as molecular chaperones with regulatory/mediatory effects on folding, maintenance/stability, maturation, and conformation of proteins as well as their effects on prevention of protein aggregation. Hsp90 ensures the stabilit...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610671/ https://www.ncbi.nlm.nih.gov/pubmed/36297655 http://dx.doi.org/10.3390/pharmaceutics14102220 |
_version_ | 1784819334165561344 |
---|---|
author | Ardestani, Mina Khorsandi, Zahra Keshavarzipour, Fariba Iravani, Siavash Sadeghi-Aliabadi, Hojjat Varma, Rajender S. |
author_facet | Ardestani, Mina Khorsandi, Zahra Keshavarzipour, Fariba Iravani, Siavash Sadeghi-Aliabadi, Hojjat Varma, Rajender S. |
author_sort | Ardestani, Mina |
collection | PubMed |
description | Heat shock proteins (Hsps) have garnered special attention in cancer therapy as molecular chaperones with regulatory/mediatory effects on folding, maintenance/stability, maturation, and conformation of proteins as well as their effects on prevention of protein aggregation. Hsp90 ensures the stability of various client proteins needed for the growth of cells or the survival of tumor cells; therefore, they are overexpressed in tumor cells and play key roles in carcinogenesis. Accordingly, Hsp90 inhibitors are recognized as attractive therapeutic agents for investigations pertaining to tumor suppression. Natural Hsp90 inhibitors comprising geldanamycin (GM), reclaimed analogs of GM including 17-AAG and DMAG, and radicicol, a natural macrocyclic antifungal, are among the first potent Hsp90 inhibitors. Herein, recently synthesized heterocyclic compounds recognized as potent Hsp90 inhibitors are reviewed along with the anticancer effects of heterocyclic compounds, comprising purine, pyrazole, triazine, quinolines, coumarin, and isoxazoles molecules. |
format | Online Article Text |
id | pubmed-9610671 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96106712022-10-28 Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications Ardestani, Mina Khorsandi, Zahra Keshavarzipour, Fariba Iravani, Siavash Sadeghi-Aliabadi, Hojjat Varma, Rajender S. Pharmaceutics Review Heat shock proteins (Hsps) have garnered special attention in cancer therapy as molecular chaperones with regulatory/mediatory effects on folding, maintenance/stability, maturation, and conformation of proteins as well as their effects on prevention of protein aggregation. Hsp90 ensures the stability of various client proteins needed for the growth of cells or the survival of tumor cells; therefore, they are overexpressed in tumor cells and play key roles in carcinogenesis. Accordingly, Hsp90 inhibitors are recognized as attractive therapeutic agents for investigations pertaining to tumor suppression. Natural Hsp90 inhibitors comprising geldanamycin (GM), reclaimed analogs of GM including 17-AAG and DMAG, and radicicol, a natural macrocyclic antifungal, are among the first potent Hsp90 inhibitors. Herein, recently synthesized heterocyclic compounds recognized as potent Hsp90 inhibitors are reviewed along with the anticancer effects of heterocyclic compounds, comprising purine, pyrazole, triazine, quinolines, coumarin, and isoxazoles molecules. MDPI 2022-10-18 /pmc/articles/PMC9610671/ /pubmed/36297655 http://dx.doi.org/10.3390/pharmaceutics14102220 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ardestani, Mina Khorsandi, Zahra Keshavarzipour, Fariba Iravani, Siavash Sadeghi-Aliabadi, Hojjat Varma, Rajender S. Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications |
title | Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications |
title_full | Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications |
title_fullStr | Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications |
title_full_unstemmed | Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications |
title_short | Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications |
title_sort | heterocyclic compounds as hsp90 inhibitors: a perspective on anticancer applications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610671/ https://www.ncbi.nlm.nih.gov/pubmed/36297655 http://dx.doi.org/10.3390/pharmaceutics14102220 |
work_keys_str_mv | AT ardestanimina heterocycliccompoundsashsp90inhibitorsaperspectiveonanticancerapplications AT khorsandizahra heterocycliccompoundsashsp90inhibitorsaperspectiveonanticancerapplications AT keshavarzipourfariba heterocycliccompoundsashsp90inhibitorsaperspectiveonanticancerapplications AT iravanisiavash heterocycliccompoundsashsp90inhibitorsaperspectiveonanticancerapplications AT sadeghialiabadihojjat heterocycliccompoundsashsp90inhibitorsaperspectiveonanticancerapplications AT varmarajenders heterocycliccompoundsashsp90inhibitorsaperspectiveonanticancerapplications |